The figure forms part of the study of the evolution of the pandemic, based on mathematical models, being carried out with the support of the "la Caixa" Foundation by a multidisciplinary group of researchers from the UPC and the IGTP. The data show that there were at least 2.5-2.7 million accumulated cases in Spain on 26 April and 600-800,000 cases in Catalonia. According to the analysis, the delay between the appearance of symptoms and registration in the official statistics is between 10 to 14 days.
At the IGTP TODAY
100 RESPIRA ventilators from GAPInnova delivered to the SEM to continue clinical trials with COVID-19 patients in other hospitals
The emergency ventilator RESPIRA, developed by GPAINNOVA, with the support of the Hospital Clínic, Barcelona, the Germans Trias i Pujol Research Institute and the University of Barcelona have passed the first stage of the clinical trial with the first two patients affected by COVID-19 successfully. With the first phase complete, the study can be expanded to other hospitals in the region. Thanks to the support received from the public, companies and administrations today the first 100 emergency ventilators c have been delivered to the SEM for distribution.
The autonomous ventilation device (DAR) developed by the Hospital Clínic Barcelona, Germans Trias i Pujol, the University of Barcelona and GASN2 is authorized by the AEMPS to start clinical trials
The Spanish Agency of Medicines and Medical Devices (AEMPS) has today given the green light to test the device developed by the company GasN2 with the support of professionals from the Hospital Clínic Barcelona, the Germans Trias i Pujol Research Institute (IGTP) and the University of Barcelona (UB). The prototype uses a system of electro pneumatic valves to supply and control the volume of oxygen necessary for each patient. Support from civil society, companies and administrations has been key to the development of the design and industrial scaling up of the model to contribute to the provision of the ventilators needed by the health system.
Two projects at the IGTP and IDIAP Jordi Gol research centres focus on the immune response of health professionals to infection with SARS-CoV-2
The IGTP has received funding in the extraordinary call published by the Department of Research and Innovation of the Department of Health (DGRIS) with the collaboration of AQuAS and Biocat and aimed at all the Iriscat centres for research into coronavirus. The two projects, focussed on the immune response of health professionals on the frontline with the virus, have joined the forces of the IGTP, IrsiCaixa and research and healthcare in the context of primary and hospital healthcare. A third project, led by Dr Julià Blanco, researcher at IrsiCaixa and the IGTP has also received funding.
The Spanish Agency of Medicines and Medical Devices (AEMPS) has approved a clinical trial with the ventilation device RESPIRA developed by GAPInnova with the support of professionals from the Hospital Clínic Barcelona, the Germans Trias I Pujol Research Institute and the University of Barcelona. This is the second device developed with the support of these organizations to be approved by the AEMPS for testing on patients at the Hospital Clinic Barcelona and at Can Ruti. The prototype of the RESPIRA device mechanizes manual ressusitations with AMBU devices providing automatic respiration assistance and monitoring.
Several research groups at the IGTP are applying their experience and knowledge to fight against coronavirus and COVID-19. None of this would be possible without help, research is a long haul activity which needs multiple players collaborating over time and we need your help.
Researchers of the Experimental Tuberculosis Unit at the IGTP have launched a questionnaire to ask the public how they are being affected by the pandemic. The project, led by Dr Cristina Vilaplana, will collect replies from the public using a standard questionnaire to evaluate the impact of the pandemic on people, including healthcare workers including effects on health, emotional wellbeing and family finances.
New ventilator device developed by the Hospital Clínic, Germans Trias i Pujol and Barcelona University with Protofy.xyz gets the go ahead from the AEMPS for clinical trials
The Spanish Agency of Medicines and Medical Devices (AEMPS) approves a clinical trial with the emergency ventilator device developed by the Barcelona company Protofy.xyz with the financial and scientific support of professionals from the Hospital Clínic Barcelona, the Germans Trias i Pujol hospital and the University of Barcelona. It is a device to automate manual ventilation processes and provide respiratory support for patients in emergency situations when conventional ventilators are unavailable. The support received from civil society, companies and administrations has been key in developing the design and industrial scaling of this model, which will contribute to providing the health system with the necessary ventilators.
Can Ruti Campus, Hospital Clínic Barcelona and Barcelona University collaborate in a Ministry of Health project to develop emergency ventilators
The Germans Trias i Pujol and Clínic Barcelona Hospitals and the University of Barcelona are providing scientific support to develop a device that allows patients to be ventilated in the absence of conventional ventilators. Three Catalan companies (Protofy.xyz, GasN2 and Innova) are creating and adapting emergency models of ventilators to deal with the crisis caused by COVID-19. The three proposals are now in the simulation and experimental phases. When they have completed all the validations and have obtained the authorization of the Spanish Agency of Medicines and Medical Devices (AEMPS) production will start on industrial scale. Support from civil society will be key in developing the three models and financing production to contribute to providing the Catalan health system with the ventilators needed.
A team including researchers at the IGTP confirm new ways to test and treat TB by harnessing the body’s own defences
In new study in a cohort of patients from Southern Europe, researchers including the innovation in Respiratory Infections and Tuberculosis Diagnosis Group at the IGTP have confirmed the importance of exploring immune pathways other than the ones modulated by interferon-gamma, which is the one that has been most studied in work on TB until now. The study published in Frontiers of Immunology has also hinted at ways to differentiate between latent and active TB, a major goal in the battle against the disease.